Bio-Pharma Division is Outpacing Projections
FY 2006 was a successful year for our Bio-Pharma Healthcare Division which exceeded growth by more than 300% over 2005. This rapid growth is a sign of good things to come. As the biotech industry continues to show rapid growth, with global revenues rising from 22.7 billion dollars to more than 50 billion dollars in the past five years, Cavalier is well positioned to provide full service "Turn-Key Cold Chain Solutions" to this market. Continue »
|
|
|
